Kostas Stamatopoulos

Dr. Kostas Stamatopoulos


Research Focus & Metrics

Academic Career Length

29Years (1998-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 July 2020 in Leukemia
Verified
Journal Article
Closed access
PDF file
LSLydia Scarfò
Lydia Scarfò
TCThomas Chatzikonstantinou
Thomas Chatzikonstantinou
GRGian Matteo Rigolin
Gian Matteo Rigolin
GQGiulia Quaresmini
Giulia Quaresmini
MMMarina Motta
Marina Motta
PGPaolo Prospero Ghia
Paolo Prospero Ghia

14 March 2019 in Blood
Verified
Journal Article
Open access
PDF file
PBPanagiotis Baliakas
Panagiotis Baliakas
SJSabine Jeromin
Sabine Jeromin
MIMichalis Iskas
Michalis Iskas
APAnna Puiggros
Anna Puiggros
KPKarla Plevova
Karla Plevova
KSKostas Stamatopoulos
Kostas Stamatopoulos
Recent evidence suggests that complex karyotype (CK) defined by the presence of ≥3 chromosomal aberrations (structural and/or numerical) identified by using chromosome-banding analysis (CBA) may be relevant for treatment decision-making in chronic lymphocytic leukemia (CLL). However, many challenges toward the routine clinical application of CBA remain. In a retrospective study of 5290 patients with available CBA data, we explored both clinicobiological associations and the clinical impact of CK in CLL. We found that patients with ≥5 abnormalities, defined as high-CK, exhibit uniformly dismal clinical outcomes, independently of clinical stage, TP53 aberrations (deletion of chromosome 17p and/or TP53 mutations [TP53abs]), and the expression of somatically hypermutated (M-CLL) or unmutated immunoglobulin heavy variable genes. Thus, they contrasted with CK cases with 3 or 4 aberrations (low-CK and intermediate-CK, respectively) who followed aggressive disease courses only in the presence of TP53abs. At the other end of the spectrum, patients with CK and +12,+19 displayed an exceptionally indolent profile. Building upon CK, TP53abs, and immunoglobulin heavy variable gene somatic hypermutation status, we propose a novel hierarchical model in which patients with high-CK exhibit the worst prognosis, whereas those with mutated CLL lacking CK or TP53abs, as well as CK with +12,+19, show the longest overall survival. Thus, CK should not be axiomatically considered unfavorable in CLL, representing a heterogeneous group with variable clinical behavior. High-CK with ≥5 chromosomal aberrations emerges as prognostically adverse, independent of other biomarkers. Prospective clinical validation is warranted before ultimately incorporating high-CK in risk stratification of CLL.

4 November 2016 in Leukemia
Verified
Journal Article
Closed access
KSKostas Stamatopoulos
Kostas Stamatopoulos
AAA Agathangelidis
A Agathangelidis
RRR Rosenquist
R Rosenquist
PGPaolo Prospero Ghia
Paolo Prospero Ghia

11 March 2021 in Blood
Verified
Journal Article
Open access
PDF file
AAAndreas Agathangelidis
Andreas Agathangelidis
ACAnastasia Chatzidimitriou
Anastasia Chatzidimitriou
KGKaterina Gemenetzi
Katerina Gemenetzi
VGVéronique Giudicelli
Véronique Giudicelli
MKMaria Karypidou
Maria Karypidou
KSKostas Stamatopoulos
Kostas Stamatopoulos
Chronic lymphocytic leukemia (CLL) is characterized by the existence of subsets of patients with (quasi)identical, stereotyped B-cell receptor (BcR) immunoglobulins. Patients in certain major stereotyped subsets often display remarkably consistent clinicobiological profiles, suggesting that the study of BcR immunoglobulin stereotypy in CLL has important implications for understanding disease pathophysiology and refining clinical decision-making. Nevertheless, several issues remain open, especially pertaining to the actual frequency of BcR immunoglobulin stereotypy and major subsets, as well as the existence of higher-order connections between individual subsets. To address these issues, we investigated clonotypic IGHV-IGHD-IGHJ gene rearrangements in a series of 29 856 patients with CLL, by far the largest series worldwide. We report that the stereotyped fraction of CLL peaks at 41% of the entire cohort and that all 19 previously identified major subsets retained their relative size and ranking, while 10 new ones emerged; overall, major stereotyped subsets had a cumulative frequency of 13.5%. Higher-level relationships were evident between subsets, particularly for major stereotyped subsets with unmutated IGHV genes (U-CLL), for which close relations with other subsets, termed “satellites,” were identified. Satellite subsets accounted for 3% of the entire cohort. These results confirm our previous notion that major subsets can be robustly identified and are consistent in relative size, hence representing distinct disease variants amenable to compartmentalized research with the potential of overcoming the pronounced heterogeneity of CLL. Furthermore, the existence of satellite subsets reveals a novel aspect of repertoire restriction with implications for refined molecular classification of CLL.

26 October 2013 in American Journal of Hematology
Verified
Journal Article
Closed access
PDF file
PBPanagiotis Baliakas
Panagiotis Baliakas
MIMichalis Iskas
Michalis Iskas
AGAnne Gardiner
Anne Gardiner
ZDZadie Davis
Zadie Davis
KPKarla Plevova
Karla Plevova
DODavid Oscier
David Oscier

29 January 2015 in Blood
Verified
Journal Article
Open access
PDF file
PBPanagiotis Baliakas
Panagiotis Baliakas
AAAndreas Agathangelidis
Andreas Agathangelidis
AHAnastasia Hadzidimitriou
Anastasia Hadzidimitriou
LSLesley-Ann Sutton
Lesley-Ann Sutton
EMEva Minga
Eva Minga
KSKostas Stamatopoulos
Kostas Stamatopoulos
Key Points: CLL stereotyped subset #2 (IGHV3-21/IGLV3-21) is uniformly aggressive independently of somatic hypermutation status. The prognosis for non–subset #2/IGHV3-21 CLL resembles that of the remaining CLL cases with similar somatic hypermutation status.